Pharsight

Pluvicto is owned by Aaa Usa Novartis.

Pluvicto contains Lutetium Lu-177 Vipivotide Tetraxetan.

Pluvicto has a total of 3 drug patents out of which 0 drug patents have expired.

Pluvicto was authorised for market use on 23 March, 2022.

Pluvicto is available in solution;intravenous dosage forms.

Pluvicto can be used as for treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy.

Drug patent challenges can be filed against Pluvicto from 2026-03-23.

The generics of Pluvicto are possible to be released after 17 October, 2034.

Application	Filing Date	Opposition Party	Legal Status
EP08798020A	2020-07-07	Orano Med	Revoked
EP08798020A	2020-07-07	Boult Wade Tennant LLP	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11318121	AAA USA NOVARTIS	PSMA binding ligand-linker conjugates and methods for using	Aug, 2028 (5 years from now)
US10406240	AAA USA NOVARTIS	PSMA binding ligand-linker conjugates and methods for using	Aug, 2028 (5 years from now)
US10398791	AAA USA NOVARTIS	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	Oct, 2034 (11 years from now)

Do you want to check out PLUVICTO patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 2026-03-23

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...

Dosage: SOLUTION;INTRAVENOUS